# Prostate Cancer Genetic Risk Evaluation and Screening Study

> **NCT05129605** · — · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Prostatic Neoplasm
- Prostate Cancer
- BRCA2 Mutation
- BRCA1 Mutation
- ATM Gene Mutation
- MMR Mutation
- Lynch Syndrome
- Genetic Predisposition to Disease

## Interventions

- **DIAGNOSTIC_TEST:** Prostate cancer screening

## Key facts

- **NCT ID:** NCT05129605
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-12
- **Primary completion:** 2030-12
- **Final completion:** 2040-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05129605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05129605, "Prostate Cancer Genetic Risk Evaluation and Screening Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05129605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*